Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapy for chronic hepatitis B infection

N A Terrault1, T L Wright

  • 1Department of Medicine, Veterans Administration Medical Center, San Francisco, California, USA.

Advances in Experimental Medicine and Biology
|January 1, 1996
PubMed
Summary

Interferon-alpha therapy for chronic hepatitis B virus (HBV) shows limited efficacy and significant drawbacks. New, orally available, and cost-effective treatments are urgently needed for the millions affected worldwide.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Property of Alcohol Which Allures the Neurotic to Drink.

The Southern medical record·2022
Same author

Racial and Ethnic Differences in Graft Loss Among Female Liver Transplant Recipients.

Transplantation proceedings·2018
Same author

Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.

Alimentary pharmacology & therapeutics·2018
Same author

Suspected Hepadnavirus Association with a Hepatocellular Carcinoma in a Black-Tailed Prairie Dog (Cynomys ludovicianus).

Journal of comparative pathology·2017
Same author

Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Alimentary pharmacology & therapeutics·2016

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis B virus (HBV) infection affects approximately 300 million individuals globally.
  • Interferon-alpha is the sole approved therapy in the US and Europe, offering limited response rates and significant side effects.
  • Long-term outcomes and complications associated with interferon-alpha treatment for chronic HBV remain incompletely understood.

Purpose of the Study:

  • To review the current landscape of chronic HBV treatment.
  • To highlight the limitations of existing therapies, particularly interferon-alpha.
  • To explore promising alternative therapeutic strategies for chronic HBV infection.

Main Methods:

  • Literature review of current and emerging treatments for chronic HBV.
  • Analysis of the efficacy, side effects, and cost-effectiveness of interferon-alpha therapy.
  • Evaluation of nucleoside analogues, therapeutic vaccines, and combination therapies as potential alternatives.

Main Results:

  • Interferon-alpha achieves loss of HBeAg and HBV DNA in only about one-third of patients.
  • Treatment is associated with significant side effects, requires subcutaneous administration, and is costly.
  • A substantial proportion of patients (over 60%) are non-responders or ineligible for interferon-alpha therapy.

Conclusions:

  • Current therapies for chronic HBV are suboptimal, necessitating the development of improved treatment options.
  • Nucleoside analogues show significant promise as effective, orally-available, and potentially more cost-effective treatments.
  • Further research into novel agents, therapeutic vaccines, and combination strategies is crucial for managing chronic HBV infection globally.

Related Experiment Videos